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Methicillin-resistant Staphylococcus aureus
(MRSA) is often resistant to most other antibiotics,
frequently causes nosocomial infections, and is one
of the greatest challenges for modern antimicro-
bial therapy, particularly since the emergence of 
S. aureus with intermediate susceptibility to gly-
copeptides [1]. In the early 1990s, a European
survey indicated that MRSA tended to be more
frequent in southern than in northern Europe. In
countries such as France, Spain, and Italy more
than 30% of S. aureus isolates were resistant to me-
thicillin [2]. This was further confirmed in a more
Objective: To assess the epidemiology of me-
thicillin-resistant Staphylococcus aureus (MRSA) in
Switzerland.
Material and methods: One-year national sur-
vey of all MRSA cases detected in a large sample
of Swiss healthcare institutions (HCI). Analysis 
of epidemiological and molecular typing data
(PFGE) of MRSA strains.
Results: During 1997, 385 cases of MRSA were
recorded in the 5 university hospitals, in 33 acute
care community hospitals, and 14 rehabilitation or
long-term care institutions. Half of the cases were
found at the University of Geneva Hospitals where
MRSA was already known to be endemic (41.1
cases/10,000 admissions). The remaining cases
(200) were distributed throughout Switzerland.
The highest rates (>100 cases/10,000 admissions)
were reported from non-acute care institutions.
Rates ranged from 3.3 to 41.1 cases/10,000 admis-
sions for university hospitals (mean 15.5); 0.67 to
90.4 for community hospitals (mean 4.8), and 28.2
to 315 for non-acute care institutions reporting
MRSA (mean 85.7). Forty percent of MRSA
patients were infected, while 60% were only
colonised. The leading infection sites were skin
and soft tissue (21%), surgical site (15%), and the
urinary tract (26%). Whereas in Eastern Swiss
HCI most MRSA cases occurred in acute care hos-
pitals (n = 47, 98%), rehabilitation and long-term
care institutions accounted for an important num-
ber of the identified cases (n = 107, 38%) in West-
ern Switzerland.
Conclusion: Low rates of MRSA were still ob-
served in Swiss HCI, despite one outlying acute
care centre with endemic MRSA and some non-
acute care institutions with epidemic MRSA. Re-
habilitation and long-term care institutions con-
tributed to a substantial proportion of cases in
Western Switzerland and may constitute a signi-
ficant reservoir. Overall, a national approach to
surveillance and control of MRSA is mandatory in
order to preserve a still favourable situation, and to
decrease the risk of epidemic MRSA dissemina-
tion.
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Introduction
recent survey [3]. However, within a country,
MRSA prevalence may vary substantially from one
hospital to another [4].
Although the reported proportion of MRSA
among all S. aureus isolates in countries surround-
ing Switzerland is high, low rates (0 to 4%) have
been reported in Swiss hospitals [5, 6], with the ex-
ception of the University of Geneva Hospitals
(HUG) (20%) [7]. The objective of the present
study was to establish a comprehensive picture of
the epidemiology of MRSA in Switzerland by per-
forming an extensive one-year survey.
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Material and methods
General setting and organisation of the survey
In Switzerland, there are 5 university hospitals for a
country of approximately 7 million inhabitants. In 1997,
these centres organised a national survey of MRSA and
collected data and isolates not only from their own hospi-
tal but, also, from other Health Care Institutions (HCI) in
their region that agreed to participate. In 1997, 445 HCI
were members of the H+ organisation (H+ The Swiss
Hospitals, Aarau, Switzerland), which represent 80–90%
of all Swiss HCI, without the nursing homes.
MRSA detection and control measures 
at the hospital level
Surveillance screening and control measures used in
the participating institutions were standardised for the
purpose of the study [6]. In brief, patients with MRSA
were identified by surveillance of microbiological labora-
tory data from clinical specimens as well as by cultures ob-
tained from roommates of patients infected or colonised
with MRSA. When a cluster was suspected, patients of the
concerned ward were screened. In addition, surveillance
cultures were performed on readmission of patients
previously known to have been positive for MRSA and on
patients transferred from foreign hospitals. At HUG, an
automatic alert system allowed immediate recognition and
admission screening of patients previously know as MRSA
carriers [8]. Cultured sites included anterior nares, per-
ineal (or perirectal), and any infected sites such as open
wounds.
A standard isolation procedure was applied to all pa-
tients positive for MRSA. The decolonisation procedure
consisted of the application of nasal mupirocin (Bac-
troban) twice daily for 5 days, associated with a daily body
wash with a chlorhexidine-containing soap for 7 to 10
days. Isolation was stopped when decolonisation was
documented by two sets of negative surveillance cultures
obtained at least 48 h apart. Patients with infections re-
ceived appropriate antibiotic therapy.
Bacterial isolates
MRSA isolates were collected by the laboratories of
the university centres. Identification of S. aureus was
confirmed by standard methods and susceptibility testing
was performed by disk diffusion on Mueller-Hinton agar
with 24-h incubation at 35 °C. Interpretation criteria were
those of the National Committee for Clinical Laboratory
Standards (NCCLS) [9]. Resistance to oxacillin was con-
firmed by the screen agar test [10] and on random isolates
by amplification of the mecA gene.
Epidemiological data and definitions
A case was defined as a hospitalised patient found to
be infected or colonised with MRSA during the study pe-
riod. For each case, the following characteristics and risk
factors for MRSA colonisation/infection were recorded:
demographic data, geographic origin, admission and dis-
charge dates, prior hospitalisation during the preceding 3
years, past history of MRSA colonisation or infection,
presence of comorbidities (Charlson score [11]), func-
tional status (Karnofsky index [12]), underlying diagnosis,
infection versus colonisation with MRSA, presence of
indwelling urinary or vascular catheter, wound, drains,
endotracheal tube, antibiotic treatment and operation.
Cases considered as having acquired MRSA before
admission (pre-hospitalisation acquisition) were: (1) pa-
tients known to have been colonised/infected with MRSA
during a prior hospitalisation; (2) cases with MRSA de-
tected within 72 h of admission; and (3) cases where the
isolate exhibited a PFGE pattern observed only once
(unique) in a given hospital (thus presumed to have been
introduced by the patient). Other cases were considered
as newly hospital-acquired MRSA.
Standard definitions for nosocomial infections of the
Centers for Diseases Control and Prevention (CDC) were
used [13]. A case was considered infected by MRSA (as op-
posed to colonised) when MRSA was isolated from a
sterile site, or when signs of infection motivated systemic
antibiotic therapy and/or surgical procedure.
Results
General data
From January to December 1997, 385 cases 
of MRSA were identified and reported from the 
5 university hospitals, 33 other acute care hospi-
tals, and 14 rehabilitation or long-term care insti-
tutions throughout the country (table 2, figure 1).
Ten additional HCI reported not to have observed
any MRSA cases. Both epidemiological data and
isolates were available for 225 (63%) of the cases,
whereas only epidemiological data or isolates were
available for 97 and 63 cases, respectively. 
Demographic and clinical characteristics of
the MRSA cases are shown in table 1. Variations in
the origin of the patients between institutions were
observed (table 2). Although 52% of the patients
were admitted from their home 92% had been hos-
pitalised in the previous 3 years. Transfer from an-
other hospital (within or outside Switzerland) was
the next most frequent origin of cases.
MRSA rates
The proportions of MRSA among all S. aureus
isolates were 4, 3, 23, 3, and 6% in Basel, Bern,
Geneva, Lausanne, and Zurich university hospi-
tals, respectively. The highest number of MRSA
cases/10,000 admissions in a university hospital
was found at HUG (41.1), whereas it was below
10/10,000 admissions in the other university hos-
pitals (table 2). The mean rate was 4.8 cases/10,000
admissions in acute community hospitals (range
0.67 to 90.4) and 85.7/10,000 admissions in reha-
bilitation and long-term care institutions that
reported MRSA cases (range 28.2 to 315). The
incidence-density of all MRSA cases averaged
0.93/10,000 patient-days, and varied from 0.2 to
2.1 in university hospitals (mean 1.2), from 0.06 to
3.0 (mean 0.47) in other acute care hospitals, and
from 0.6 to 13.5 (mean, 2.2) in rehabilitation or
long-term care institutions.
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Mean age (range) 66 (0–99)
Sex (male) 212/376 (57%)
Presence of comorbidities 199/276 (72%)
Indwelling urinary catheter 98/267 (37%)
Vascular catheter 159/269 (59%)
Wounds 130/211 (62%)
Drains 31/262 (12%)
Endotracheal tube 48/265 (18%)
Operation 70/264 (17%)
Antibiotic treatment 177/245 (72%)
Haemodialysis 1/284 (0.3%)
Table 1
Demographic and
clinical characteris-
tics of the MRSA
cases.
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Figure 1 
A. Geographical
distribution of MRSA
cases in Switzerland,
1997. Each circle rep-
resents one institu-
tion, the number in
the circle is the num-
ber of MRSA cases
reported for this
institution.
University hospitals Other health care institutions Total
Basel Bern Geneva Lausanne Zurich acute care non acute
(N = 25) care (N = 14)
No. of cases 8 12 185 24 18 85 53 385
Origin1,2 (%): N = 33 N = 16 N = 296
home 5 (71%) 3 (25%) 103 (79%) 11 (46%) 5 (28%) 16 (49%) 10 (41%) 153 (52%)
nursing home 0 0 6 (5%) 2 (8%) 2 (11%) 9 (27%) 2 (20%) 21 (7%)
transfer from Swiss hospital 1 (14%) 2 (17%) 7 (5%) 4 (17%) 4 (22%) 7 (21%) 4 (37%) 29 (10%)
transfer from a hospital 
outside Switzerland 1 (14%) 6 (50%) 9 (7%) 7 (29%) 6 (33%) 0 0 29 (10%)
other origin 0 1 (8%) 6 (5%) 0 0 1 (3%) 0 8 (3%)
Prior hospitalisation2 8/8 (100%) 9/10 (90%) 169/184 (92%) 23/24 (96%) 15/16 (94%) 26/30 (87%) 14/15 (93%) 264/287 (92%)
No. of cases / 10’000 adm.2 3.5 3.3 41.1 9.3 6.1 4.8 85.7 10.6
No. of cases / 
10’000 patient-days2 0.24 0.37 2.1 1.15 0.79 0.47 2.2 0.93
No. of infections/
10’000 admissions2 0.4 1.4 13.8 1.6 2.7 n.a. n.a. n.a.
1 during the previous 3 years.
2 for cases for whom data was known.
n.a., not available
Table 2
Incidence and demographic characteristics of MRSA cases.
Hospitalisation ward
Table 3 shows the wards on which patients
were hospitalised at time of detection. Most cases
(72%) occurred in medical or surgical units.
MRSA observed in intensive care units (ICUs) rep-
resented less than 8% of cases in Western Swiss
hospitals whereas, in Eastern Switzerland, they
accounted for 21%. Of note, among the 20 cases
which occurred in Swiss ICUs, 9 (45%) were trans-
ferred from foreign hospitals.
Type of institution
The distribution of cases according to the type
of institution (acute hospitals of various sizes, re-
habilitation, and long-term care facilities) is shown
in table 4. In Western Swiss HCI, between 24 and
39% of cases were observed in non-acute care in-
stitutions (rehabilitation and long-term care facil-
ities) whereas this proportion was below 2% in
Eastern and Southern Switzerland. Analysis of
molecular data showed that 86% (48/56) of cases
in non-acute care wards of Western Switzerland
were due to an epidemic clone. By comparison, this
clone accounted for only 40% (19/47) of the cases
observed in acute care hospitals.
Prior versus new acquisition of MRSA
For the university hospitals, the epidemio-
logical data permitted determination of whether
MRSA had most likely been acquired before 
(= prior acquisition) or during the hospitalisation
considered in the study (= new acquisition) (table
5). Overall, 86/309 (28%) cases were considered to
have been newly-acquired MRSA. The rates var-
ied from 8.3 to 29% between the different univer-
sity hospitals. Based on this data, the attack rate of
MRSA, defined as the number of newly-acquired
MRSA while admitted to the different university
hospitals, averaged 2.8 ranging from 0.3 to 8.1
cases/10,000 admissions.
Among the 144 cases with prior acquisition of
MRSA and for which data were available, 94 (65%)
came from home, 36 (25%) were transferred from
Swiss (7%) or foreign (18%) hospitals, and 9 (6%)
from non-acute care institutions. Among patients
admitted directly from home, 92% of cases had
been hospitalised previously (table 2).
MRSA infections
Overall, 116/291 (40%) of cases were consid-
ered as having clinical infections with a total of 138
infections. Infection rates ranged from 0.4 to
13.8/10,000 admissions in university hospitals
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Wards HUG Western CH Eastern CH Total
N = 126 N = 56 N = 47 N = 229
Acute
Emergency 0 17.8 8.5 6.1
ICU 4.8 7.1 21.3 8.7
Medicine 50.8 37.5 21.3 41.5
Surgery 34.1 26.8 25.5 30.6
Paediatrics 6.3 5.4 6.4 6.1
Other 4.0 5.4 17.0 7.0
Total 100 100 100 100
Table 3
Proportions (in %) 
of MRSA cases in 
the different wards 
of acute institutions
in each geographical
region (HUG, and
other hospitals of
Western Switzerland
and Eastern Switzer-
land; data not avail-
able for Southern
Switzerland).
Geneva Western Eastern Southern 
area CH CH CH
N = 178 N = 113 N = 59 N = 25
Acute 
University hospitals 76.4 21.2 67.8
Community hospitals
>500 beds 10.1
250–499 beds 15.0 5.0 24
125–244 11.5 11.9 36
<125 14.2 3.4 40
Non acute
Rehabilitation 23.6 28.3
Long-term care 9.7 1.7
Total 100 100 100 100
Table 4
Proportions (%) of
MRSA cases in the
different institutions
of each geographical
region: Geneva area,
Western Switzerland
(Geneva excluded),
Eastern and Southern
Switzerland.
Basel Bern Geneva Lausanne Zurich Total
Prior acquisition (n) 5 11 129 19 15 179
New acquisition (n) 2 1 31 5 3 42
Undetermined1 (n) 1 0 25 0 0 26
New / [prior + new] (%) 29% 8.3% 19% 21% 17% 19%
No. new /10,000 admissions 0.9 0.3 8.1 1.9 1.0 2.8
1 no data available
Table 5
Prior versus new
acquisition of MRSA
in the different uni-
versity hospitals.
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Figure 2
Frequency of MRSA
infection sites 
(N = 138).
(table 2). Data were not available for most other
HCI. The leading infection sites were the urinary
tract (25%), skin and soft tissue (20%) and the
surgical site (15%) (figure 2). No significant dif-
ference in the distribution of the sites of infection
was observed between the different hospitals.
Molecular epidemiology
Molecular typing (pulsed field gel electro-
phoresis) was performed on isolates of 288/385 of
the cases (one isolate per case). Detailed results
have been published elsewhere [25]. Results
showed that 65% of the isolates belonged to four
predominant clones, three of which were mostly
present in Geneva hospitals (figures 3 and 4). The
remaining 35% of the isolates were clustered into
67 genotypes and they accounted for 1 to 5 patients
per hospital (figure 3).
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Figure 3
Distribution of geno-
types in community
and university (Basel,
Bern, Geneva, Lau-
sanne and Zurich)
hospitals (one strain
per case). The four
predominant clones
(WCH, GE1, GE2 and
GE3) are represented
by their major type
(1, 9, 40 and 57, re-
spectively) and their
subtypes (letters).
Reproduced with the
permission of Clinical
Microbiology and
Infection [25].
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Geographical distri-
bution of the four
predominant clones
of MRSA in Switzer-
land in 1997 (one
symbol per institu-
tion and per clone,
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This study is the first nationwide survey on
MRSA carried out in Switzerland. The results
confirm that Swiss HCI have a low prevalence of
MRSA, with the exception of the HUG and some
non-acute care institutions in the western part of
the country [8, 14].
Although a substantial number of institutions
participated in the study, our results are derived
from a convenience sample of hospitals that vol-
unteered to participate, and cannot be extrapolated
to the whole of Switzerland for two reasons. First,
university hospitals which have all participated in
the study, represent a non-negligible bias since risk
factors for MRSA are much higher in this type of
institution. Second, although we received data
from 10 community hospitals reporting no MRSA
during the period of the survey, we had no data
from the other Swiss healthcare centres. However,
regarding the relatively low number of MRSA
cases recovered in most of the reporting institu-
tions and taking into account the tight network
among Swiss infection control practitioners, it is
unlikely that non-reporting institutions have ex-
perienced a substantial MRSA burden.
Different methods of calculation can be used
to measure the magnitude of MRSA occurrence at
a particular institution. The least informative fig-
ure, but also the most frequently reported as it is
the easiest to obtain and relies only on microbiol-
ogy laboratory data, is the proportion of MRSA
among all S. aureus isolates in an institution. This
proportion allows a rough comparison between
hospitals, although it also requires precise defini-
tions (eg, one isolate per patient). Thus, the HUG,
with 23%, have a rate comparable to hospitals 
of countries surrounding the southern part of
Switzerland [2, 15–17]. The other Swiss institu-
tions showed proportions below 5%, figures which
are comparable to northern European hospitals
such as those in Germany [2], the Netherlands [2,
18, 19], Denmark [2] or in Sweden [2, 20]. In Ger-
many, an increase of the proportion of S. aureus
strains resistant to methicillin from 1.7% to 12.9%
has been reported between 1990 and 1995 [21].
The number of infected or colonised MRSA
cases/10,000 admissions, or the number of MRSA
infections/10,000 admissions provide more appro-
priate figures for comparison between institutions
or for longitudinal surveillance. With 0.4 to 2.7
MRSA infections/10,000 admissions, our study
shows that university hospitals in Switzerland cur-
rently have a low incidence of MRSA, with the
exception of HUG where a rate of 13.8 infec-
tions/10,000 admissions was reported. By compar-
ison, MRSA-infected patients/10,000 admissions
in 43 French hospitals were recently estimated to
range between 18 to 158 [22]. It was estimated at
165/10,000 admissions in Irish hospitals [23]. The
incidence density (number of cases per patient-
day) may be the best indicator for comparison be-
tween institutions. Indeed, in the present study, the
incidence seems quite high in long-term care in-
stitutions when using the number of cases/10’000
admissions, but is much more comparable to uni-
versity hospitals when looking at the incidence
density (patients stay longer in long-term care
hospitals, therefore there are fewer admissions for
more patient-days of stay).
The study also shows that the epidemiology of
MRSA in Switzerland differs from one region to
another. The highest reported incidences of
MRSA cases (>100 cases/10,000 admissions) was
reported from non-acute care institutions (reha-
bilitation and long-term care), in particular in the
western part of the country. Importantly, whereas
the high number of cases of Western Switzerland
were reported from the non-acute institutions,
these institutions did not seem to play a major role
in Eastern and Southern Switzerland. A recruit-
ment bias between Western and Eastern Switzer-
land can, nevertheless, not be excluded. As the ma-
jority of the cases in non-acute care institutions
were due to an epidemic clone [24], these institu-
tions probably played an important role in the dis-
semination of the clone, as transfers of patients
from and to acute care hospitals are frequent.
These institutions might serve as a reservoir for
MRSA and infection control strategies are manda-
tory to limit the spread of the MRSA within these
HCI and reduce MRSA transfer to others.
Owing to a higher prevalence of MRSA in
HUG, one aim of this study was to establish to
what extent this potential reservoir could spread to
other western institutions in Switzerland. Part of
the answer is given by the results of molecular typ-
ing of these isolates [25] which showed that: (1) 3
clones are responsible for the majority (73%) of
the cases at HUG; (2) these clones were rarely ob-
served in other hospitals; and (3) the majority of
the cases in the western part of Switzerland, ex-
cluding Geneva, was due to a fourth epidemic
clone [24]. Thus, it seems that HUG faced mainly
a geographically-limited problem which did not
extend to the rest of Switzerland. As described for
Western Switzerland, non-acute care beds were
responsible for a large proportion of MRSA cases
at HUG.
An important finding of the present study was
that MRSA cases in ICUs accounted for less than
9% of all cases, as compared with other European
hospitals where the majority of cases are observed
in these units. However, the proportion was some-
what higher in the eastern part of Switzerland. An-
other important finding is the fact that in univer-
sity hospitals, less than 30% of cases can be con-
sidered as having acquired their MRSA during the
hospitalisation, the remaining 70% being proba-
bly acquired during previous hospital stays. Fi-
nally, the attack rate of MRSA transmission, which
could only be assessed appropriately in university
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Discussion
hospitals, remains extremely low in Switzerland
with an average incidence of 2.8 cases/10,000 ad-
missions. This illustrates the efficacy of infection
control programs, even in hospitals with high
endemicity or surrounded by known acute care
facilities with extremely high numbers of MRSA
patients, probably resulting from an ongoing 
outbreak.
In conclusion, the study confirms and extends
previous data and shows that most Swiss hospitals
have a low incidence of MRSA, despite some out-
lying institutions with endemic or highly epidemic
MRSA conditions and neighbouring countries
with a high prevalence. This might be the result of
an “aggressive” policy of MRSA surveillance and
control [6, 14]. Overall, a national approach to sur-
veillance and control of MRSA is warranted in
Switzerland in order to prevent conditions arising
which favour its further development, thereby de-
creasing the risk of epidemic MRSA transmission.
A special thanks to all Swiss hospitals and laborato-
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